PBMWW
Psyence Biomedical Ltd.
Price Chart
Latest Quote
$0.02
+0.00 (+0.00%)
Current Price
| Previous Close | $0.02 |
| Open | $0.02 |
| Day High | $0.03 |
| Day Low | $0.02 |
| Volume | 1,040 |
Stock Information
| Cash Equivalents | $7.15M |
| Net Income | $-3.94M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Income | $-3.94M |
| Book/sh | $39.62 |
| Employees | 12 |
Financial Ratios
| Quick Ratio | 7.77 |
| Current Ratio | 8.09 |
Returns & Margins
| ROA | -34.44% |
| ROE | -74.29% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.02 |
| SMA50 | $0.02 |
| RSI | nan |
| Shares Float | 142K |
| Volatility | 1.65 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +0.00% |
| YTD | +0.00% |
| 10 Years | +0.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.02 | 0 |
| 2026-06-17 | $0.02 | 0 |
| 2026-06-16 | $0.02 | 0 |
| 2026-06-15 | $0.02 | 0 |
| 2026-06-12 | $0.02 | 0 |
| 2026-06-11 | $0.02 | 0 |
| 2026-06-10 | $0.02 | 0 |
| 2026-06-09 | $0.02 | 0 |
| 2026-06-08 | $0.02 | 0 |
| 2026-06-05 | $0.02 | 0 |
| 2026-06-04 | $0.02 | 0 |
| 2026-06-03 | $0.02 | 0 |
| 2026-06-02 | $0.02 | 0 |
| 2026-06-01 | $0.02 | 0 |
| 2026-05-29 | $0.02 | 0 |
| 2026-05-28 | $0.02 | 0 |
| 2026-05-27 | $0.02 | 0 |
| 2026-05-26 | $0.02 | 0 |
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $9,270 | $52,941 | $0 | - |
| Total Expenses | $3,663,022 | $44,233,429 | $3,234,869 | $1,855,947 |
| Other Income Expense | $4,588,295 | $-6,874,811 | $26,912 | $-2,288 |
| Other Non Operating Income Expenses | $4,063,193 | $-4,386,341 | - | - |
| Net Non Operating Interest Income Expense | $86,517 | $-50,807 | $1,554 | $0 |
| Interest Expense Non Operating | $9,270 | $52,941 | $0 | - |
| Operating Expense | $3,663,022 | $44,233,429 | $3,234,869 | $1,855,947 |
| Selling And Marketing Expense | $483,530 | $80,603 | $7,029 | $17,511 |
| General And Administrative Expense | $2,833,056 | $1,716,388 | $1,618,945 | $1,701,199 |
| Other Operating Expenses | - | $41,481,605 | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $1,011,790 | $-51,159,048 | $-3,206,403 | $-1,858,235 |
| Net Interest Income | $86,517 | $-50,807 | $1,554 | $0 |
| Interest Income | $95,787 | $2,134 | $1,554 | $0 |
| Normalized Income | $565,453 | $-48,670,578 | $-3,233,315 | $-1,855,947 |
| Net Income From Continuing And Discontinued Operation | $1,011,790 | $-51,159,048 | $-3,206,403 | $-1,858,235 |
| Net Income Common Stockholders | $1,011,790 | $-51,159,048 | $-3,206,403 | $-1,858,235 |
| Net Income | $1,011,790 | $-51,159,048 | $-3,206,403 | $-1,858,235 |
| Net Income Including Noncontrolling Interests | $1,011,790 | $-51,159,047 | $-3,206,403 | $-1,858,235 |
| Net Income Continuous Operations | $1,011,790 | $-51,159,047 | $-3,206,403 | $-1,858,235 |
| Pretax Income | $1,011,790 | $-51,159,047 | $-3,206,403 | $-1,858,235 |
| Special Income Charges | $0 | $-2,179,525 | $0 | - |
| Interest Income Non Operating | $95,787 | $2,134 | $1,554 | $0 |
| Operating Income | $-3,663,022 | $-44,233,429 | $-3,234,869 | $-1,855,947 |
| Depreciation Amortization Depletion Income Statement | $4,268 | $240 | $0 | - |
| Depreciation And Amortization In Income Statement | $4,268 | $240 | $0 | - |
| Depreciation Income Statement | $4,268 | $240 | $0 | - |
| Other | ||||
| Tax Effect Of Unusual Items | $78,765 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $500,226 | $-48,617,396 | $-3,233,315 | $-1,853,660 |
| Total Unusual Items | $525,102 | $-2,488,470 | $26,912 | $-2,288 |
| Total Unusual Items Excluding Goodwill | $525,102 | $-2,488,470 | $26,912 | $-2,288 |
| Reconciled Depreciation | $4,268 | $240 | $0 | - |
| EBITDA (Bullshit earnings) | $1,025,328 | $-51,105,866 | $-3,206,403 | $-1,855,947 |
| EBIT | $1,021,060 | $-51,106,106 | $-3,206,403 | $-1,855,947 |
| Diluted NI Availto Com Stockholders | $1,011,790 | $-51,159,048 | $-3,206,403 | $-1,858,235 |
| Restructuring And Mergern Acquisition | $0 | $2,461,025 | $0 | - |
| Gain On Sale Of Security | $525,102 | $-308,945 | $26,912 | $-2,288 |
| Research And Development | $342,168 | $954,593 | $1,608,895 | $137,237 |
| Selling General And Administration | $3,316,586 | $1,796,991 | $1,625,974 | $1,718,710 |
| Other Gand A | $2,833,056 | $1,716,388 | $1,618,945 | $1,701,199 |
| Other Special Charges | - | $-281,500 | - | - |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $6,722,004 | $-10,972,540 | $-200,445 | $1,700,252 |
| Total Assets | $7,316,370 | $1,132,159 | $1,590,255 | $1,832,014 |
| Total Non Current Assets | $756,096 | $5,487 | $0 | $0 |
| Investmentin Financial Assets | $745,000 | $0 | - | - |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $745,000 | $0 | - | - |
| Current Assets | $6,560,274 | $1,126,672 | $1,590,255 | $1,832,014 |
| Restricted Cash | $35,964 | $29,611 | $29,556 | $36,226 |
| Prepaid Assets | $251,796 | $322,126 | $77,050 | $5,390 |
| Receivables | $137,348 | $41,747 | $149,369 | $39,546 |
| Other Receivables | $137,348 | $41,747 | $149,369 | $39,546 |
| Cash Cash Equivalents And Short Term Investments | $6,135,166 | $733,188 | $1,334,280 | $1,750,851 |
| Cash And Cash Equivalents | $6,135,166 | $733,188 | $1,334,280 | $1,750,851 |
| Cash Financial | $6,135,166 | $733,188 | $1,334,280 | $1,750,851 |
| Debt | ||||
| Net Debt | - | $9,714,701 | - | - |
| Total Debt | - | $10,447,889 | - | - |
| Current Debt And Capital Lease Obligation | - | $10,447,889 | - | - |
| Current Debt | - | $10,447,889 | - | - |
| Other Current Borrowings | - | $10,447,889 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $594,366 | $12,104,699 | $1,790,700 | $131,762 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $594,366 | $12,104,699 | $1,790,700 | $131,762 |
| Other Current Liabilities | $200,096 | $901,608 | - | - |
| Payables And Accrued Expenses | $312,418 | $688,303 | $1,790,700 | $131,762 |
| Payables | $261,937 | $562,352 | $1,628,143 | $36,889 |
| Accounts Payable | $261,937 | $562,352 | $1,628,143 | $36,889 |
| Equity | ||||
| Common Stock Equity | $6,722,004 | $-10,972,540 | $-200,445 | $1,700,252 |
| Total Equity Gross Minority Interest | $6,722,004 | $-10,972,540 | $-200,445 | $1,700,252 |
| Stockholders Equity | $6,722,004 | $-10,972,540 | $-200,445 | $1,700,252 |
| Other Equity Interest | $1,065,705 | - | $-200,558 | $1,700,252 |
| Gains Losses Not Affecting Retained Earnings | $351,198 | $361,057 | $165,360 | - |
| Retained Earnings | $-56,447,204 | $-57,458,994 | $-6,299,946 | - |
| Other | ||||
| Ordinary Shares Number | $90,883 | $3,584 | $3,411 | $3,411 |
| Share Issued | $90,883 | $3,584 | $3,411 | $3,411 |
| Tangible Book Value | $6,722,004 | $-10,972,540 | $-200,445 | $1,700,252 |
| Invested Capital | $6,722,004 | $-524,651 | $-200,445 | $1,700,252 |
| Working Capital | $5,965,908 | $-10,978,027 | $-200,445 | $1,700,252 |
| Total Capitalization | $6,722,004 | $-10,972,540 | $-200,445 | $1,700,252 |
| Capital Stock | $61,752,305 | $46,125,397 | $5,934,141 | - |
| Common Stock | $61,752,305 | $46,125,397 | $5,934,141 | - |
| Current Provisions | $81,852 | $66,899 | - | - |
| Current Accrued Expenses | $50,481 | $125,951 | $162,557 | $94,874 |
| Investments And Advances | $745,000 | $0 | - | - |
| Net PPE | $11,096 | $5,487 | $0 | - |
| Accumulated Depreciation | $-4,508 | $-240 | $0 | - |
| Gross PPE | $15,604 | $5,727 | $0 | - |
| Machinery Furniture Equipment | $15,604 | $5,727 | - | - |
| Other Properties | - | $5,727 | - | - |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-3,744,115 | $-2,951,092 | $-1,592,080 | $-1,396,422 |
| Operating Activities | ||||
| Operating Cash Flow | $-3,734,238 | $-2,945,365 | $-1,592,080 | $-1,396,422 |
| Cash Flow From Continuing Operating Activities | $-3,734,238 | $-2,945,365 | $-1,592,080 | $-1,396,422 |
| Operating Gains Losses | $-519,312 | $28,410 | $-84,499 | - |
| Investing Activities | ||||
| Capital Expenditure | $-9,877 | $-5,727 | - | - |
| Investing Cash Flow | $-16,230 | $-5,727 | $0 | $-32,039 |
| Cash Flow From Continuing Investing Activities | $-16,230 | $-5,727 | $0 | $-32,039 |
| Net Other Investing Changes | $-6,353 | - | - | $-32,039 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $1,742,051 | $0 | $0 | - |
| Financing Cash Flow | $9,152,446 | $2,350,000 | $1,172,923 | $-1,627,576 |
| Cash Flow From Continuing Financing Activities | $9,152,446 | $2,350,000 | $1,172,923 | $-1,627,576 |
| Net Common Stock Issuance | $1,742,051 | $0 | $0 | - |
| Common Stock Issuance | $1,742,051 | $0 | $0 | - |
| Net Other Financing Charges | - | - | $1,172,923 | $-1,627,576 |
| Other | ||||
| Repayment Of Debt | $0 | $-150,000 | $0 | - |
| Issuance Of Debt | $7,410,395 | $2,500,000 | $0 | - |
| End Cash Position | $6,135,166 | $733,188 | $1,334,280 | $1,755,038 |
| Beginning Cash Position | $733,188 | $1,334,280 | $1,753,437 | $4,811,076 |
| Changes In Cash | $5,401,978 | $-601,092 | $-419,157 | $-3,056,038 |
| Net Issuance Payments Of Debt | $7,410,395 | $2,350,000 | $0 | - |
| Net Short Term Debt Issuance | $1,000,000 | $2,350,000 | $0 | - |
| Short Term Debt Payments | $0 | $-150,000 | $0 | - |
| Short Term Debt Issuance | $1,000,000 | $2,500,000 | $0 | - |
| Net Long Term Debt Issuance | $6,410,395 | $0 | $0 | - |
| Long Term Debt Issuance | $6,410,395 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-9,877 | $-5,727 | $0 | - |
| Purchase Of PPE | $-9,877 | $-5,727 | $0 | - |
| Change In Working Capital | $-386,203 | $-1,172,951 | $1,477,535 | $129,745 |
| Change In Payables And Accrued Expense | $-360,932 | $-1,035,498 | $1,659,058 | $29,564 |
| Change In Prepaid Assets | $70,330 | $-245,075 | $-71,665 | $128 |
| Change In Receivables | $-95,601 | $107,622 | $-109,858 | $100,052 |
| Other Non Cash Items | $218,412 | $43,582,435 | - | - |
| Stock Based Compensation | $0 | $317,882 | $221,287 | $332,068 |
| Unrealized Gain Loss On Investment Securities | $-4,063,193 | $5,457,667 | $0 | - |
| Depreciation Amortization Depletion | $4,268 | $240 | $0 | - |
| Depreciation And Amortization | $4,268 | $240 | $0 | - |
| Depreciation | $4,268 | $240 | $0 | - |
| Gain Loss On Investment Securities | $-509,452 | $306,250 | - | - |
| Net Foreign Currency Exchange Gain Loss | $-9,860 | $3,660 | $-84,499 | - |
| Gain Loss On Sale Of Business | $-22,967 | $0 | $0 | - |
| Net Income From Continuing Operations | $1,011,790 | $-51,159,048 | $-3,206,403 | $-1,858,235 |
Fetched: 2026-06-20